This trial is testing a new COPD medication to see if it is effective and safe.
1 Primary · 24 Secondary · Reporting Duration: Week 52, or over 52 weeks
Experimental Treatment
Non-Treatment Group
1272 Total Participants · 7 Treatment Groups
Primary Treatment: Tozorakimab · Has Placebo Group · Phase 3
Age 40 - 130 · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: